Update, 20 October, 2025 : On 15 October 2025, the Department of Health and Social Care (DHSC) issued a Medicines Supply Notification (MSN) to say that the GLP-1 agonist exenatide, which has the brand name Bydureon, has been discontinued and supplies are no longer available
Endocrinology,157, 18811894
Method of administration Intramuscular or subcutaneous injections using insulin syringes
Serious Health Complications Linked to Ozempic Some Ozempic patients in Atlanta have reported having severe side effects and medical problems
Another likely cause: Hormonal changes that affect the cardiovascular and nervous system, which can bring on lightheadedness, disorientation, or vertigo